T1	Person 0 3	Men
T2	Person 8 13	women
*	OR T2 T1
T3	Person 14 18	aged
T4	Value 19 29	> 18 years
R1	Has_value Arg1:T3 Arg2:T4	
T5	Procedure 31 47	Angiographically
T6	Qualifier 31 57	Angiographically confirmed
R2	multi Arg1:T6 Arg2:T5	
T7	Qualifier 58 63	acute
T8	Qualifier 64 71	massive
T9	Condition 72 90	pulmonary embolism
R3	Has_qualifier Arg1:T9 Arg2:T8	
R4	Has_qualifier Arg1:T9 Arg2:T7	
R5	Has_qualifier Arg1:T9 Arg2:T6	
T10	Condition 96 137	involvement of Central pulmonary arteries
R6	AND Arg1:T9 Arg2:T10	
T11	Condition 140 186	endovascular mechanical thrombus fragmentation
T12	Procedure 189 209	thrombolytic therapy
T13	Drug 217 260	recombinant tissue activator of plasminogen
T14	Temporal 329 371	in less than 48 hours before randomization
T15	Procedure 277 286	treatment
T16	Condition 310 328	pulmonary embolism
R7	AND Arg1:T15 Arg2:T16	
R8	AND Arg1:T12 Arg2:T13	
T17	Scope 140 261	endovascular mechanical thrombus fragmentation + thrombolytic therapy (using recombinant tissue activator of plasminogen)
R9	AND Arg1:T17 Arg2:T15	
R10	Has_temporal Arg1:T15 Arg2:T14	
T18	Post-eligibility 520 561	ritten informed consent signed by patient
T19	Non-representable 373 517	The patient should be randomized no earlier than 24 hours after procedures endovascular mechanical thrombus fragmentation + thrombolytic therapy
